High-dose stimulants for attention-deficit/hyperactivity disorder a review of the clinical effectiveness, safety and guidelines

This review considers the use of short, intermediate, and/or long acting stimulants, such as, methylphenidate, amphetamine, dextro-amphetamine, and lisdexamfetamine, in children and adults. Many persons with attention-deficit/hyperactivity disorder (ADHD) require individualized, optimal dose-titrati...

Full description

Bibliographic Details
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: [Ottawa] Canadian Agency for Drugs and Technologies in Health 2016, 3 March 2016
Series:Rapid response report
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
LEADER 01909nam a2200289 u 4500
001 EB002001102
003 EBX01000000000000001164003
005 00000000000000.0
007 tu|||||||||||||||||||||
008 210907 r ||| eng
245 0 0 |a High-dose stimulants for attention-deficit/hyperactivity disorder  |h Elektronische Ressource  |b a review of the clinical effectiveness, safety and guidelines  |c prepared by Canadian Agency for Drugs and Technologies in Health 
260 |a [Ottawa]  |b Canadian Agency for Drugs and Technologies in Health  |c 2016, 3 March 2016 
300 |a 1 PDF file (24 pages) 
505 0 |a Includes bibliographical references 
653 |a Attention Deficit Disorder with Hyperactivity / drug therapy 
653 |a Comparative Effectiveness Research 
653 |a Central Nervous System Stimulants / administration & dosage 
653 |a Treatment Outcome 
653 |a Practice Guidelines as Topic 
653 |a Central Nervous System Stimulants / therapeutic use 
710 2 |a Canadian Agency for Drugs and Technologies in Health 
041 0 7 |a eng  |2 ISO 639-2 
989 |b NCBI  |a National Center for Biotechnology Information 
490 0 |a Rapid response report 
856 4 0 |u https://www.ncbi.nlm.nih.gov/books/NBK355613  |3 Volltext  |n NLM Bookshelf Books  |3 Volltext 
082 0 |a 610 
520 |a This review considers the use of short, intermediate, and/or long acting stimulants, such as, methylphenidate, amphetamine, dextro-amphetamine, and lisdexamfetamine, in children and adults. Many persons with attention-deficit/hyperactivity disorder (ADHD) require individualized, optimal dose-titration to address symptoms, and it is recommended that patients start on the lowest possible dose and titrate upwards to appropriately manage symptoms. This review aims to address concerns regarding the effectiveness and safety of the use of stimulants at higher than recommended doses